Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (March 2025)
44 slides from Innate Pharma Sa Class A's investor presentation, March 2025
Slide 1: Company overview
Company overview MARCH 2025
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Innate Pharma snapshot
Innate Pharma snapshot Global, clinical-stage oncology-focused biotech company. Antibody Engineering excellence Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Eight clinical-stage assets Focused pipeline of antibodie
Slide 4: Building on a Foundation of World Class Antibody Engineering Expertise
Innate Pharma: Building on a Foundation of World Class Antibody Engineering Expertise and Clinical Execution Antibody Engineering Excellence Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Leveraging our expertise in
Slide 5: 2025: Focus on Strategic Growth Pillars
2025: Focus on 3 Strategic Growth Pillars NK-cell engagers Antibody Drug Conjugates Current Late-Stage Assets • IPH6501 (CD20) ANKET® Phase 1 • IPH4502 (Nectin-4) IND cleared, • Lacutamab positive Phase 2 data, Phase 1 FPI Jan 2025 FDA feedback on next steps, • IPH6101 (CD123) ANKET ® Phase 2 Partne
Slide 6: Building a robust pipeline on strong basics
Building a robust pipeline on strong basics Robust pipeline with Validated Science Strong track record of innovative collaborations pre-clinical and clinical assets 8 drug candidates in clinical stage including 3 proprietary and 5 in partnerships 6
Slide 7: A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets
A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undiscl
Slide 8: ANKET: Antibody-based NK cell Engager Therapeutics
@ innate pharma w ANKET’ Antibody-based NK cell Engager Therapeutics
Slide 9: The Proprietary NK cell engager platform
The Proprietary NK cell engager platform Harness NK cells through Nkp46 NK specific activating A versatile, fit-for-purpose technology that is creating an entirely new class of tri- and receptor, conserved on Tumor infiltrating NK cells tetra-specific molecules to induce synthetic immunity against c
Slide 10: Multiple ANKET programs targeting hematological malignancies and solid tumors
Multiple ANKET® programs targeting hematological malignancies and solid tumors SAR443579 progress to Ph2 in R/R AML Growing clinical pipeline New Phase 1/2 in 1L AML in combination SAR’579 / IPH6101 (CD123) Phase 1 / 2 with azacytidin + venetoclax SAR’514 / IPH6401 (BCMA) Phase 1 / 2 SAR’514/IPH6401
Slide 11: IPH6501: Innate's lead Proprietary ANKET, a novel CD20 targeted NK Cell Engager
IPH6501: Innate’s lead Proprietary ANKET®, a novel CD20 targeted tetra-specific Natural Killer Cell Engager targeting B-Cells IL-2v Tumor Associated Antigen • Provides proliferation signal targeted to NK cells • CD20 TAG NKp46 binder • NK cell activating receptor • Most specific marker of human NK c
Slide 12: IPH6501 depletes autologous CD20+ B cells with greater efficacy and lower cytokines
IPH6501: depletes autologous CD20+ B cells from HD with greater efficacy and lower induction of pro-inflammatory cytokines than a CD20-TCE Stronger B cell depletion Less pro-inflammatory cytokines IPH6501 CD20-TCE IC-NKCE-IL2v Demaria et al., Science Immunology 2024 12
Slide 13: IPH6501: Global Phase 1/2 dose finding study ongoing in B-NHL
IPH6501: Global Phase 1/2 dose finding study patient recruitment currently ongoing in relapsed /refractory B-cell non-hodgkin’s lymphoma Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma Anti- CD20 NCT06088654 CD20 First patient dosed in March 20
Slide 14: IPH6501: Potential is being recognized by external stakeholders
IPH6501: Potential is being recognized by external stakeholders Agreement with the Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial 3m USD upfront plus up to 4.9m USD in conditional tranched investments from IFL
Slide 15: IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term
IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term IPH6501 Phase 1/2 in B-NHL Safety data and preliminary Confirm activity and dose Readouts from signals of activity in CD20+ optimization in CD20+ B-NHL expansion studies in B-NHL & select B-NHL subtypes selected B-NHL subtypes (monoth
Slide 16: SAR'579 / IPH6101 promising preliminary single agent activity in R/R AML
SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR’579 (SAR443579) / IPH6101 is a trifunctional anti-CD123 NKp46-CD16 NK cell engager PHASE 1 / 2 underway in R/R AML, B-cell ALL or HR MDS Individual Patient Responses per Investigator: Dose-Escalation Phase Efficacy
Slide 17: Antibody Drug Conjugates
~~ iso) innate pharma L™ ; ; Antibody Drug Conjugates WY y g Jug
Slide 18: Leveraging antibody expertise by developing differentiated ADCs
ADC We are leveraging our antibody expertise by developing differentiated ADCs asset to the clinic Phase 1 IPH4502 (Nectin-4) IPH43 (MICA/B) Phase 1 Research Target (Tumor antigen) Research Research 19
Slide 19: IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC Phase 1 underway Payload Exatecan, Binder a Topoisomerase I inhibitor Proprietary humanized • Active in EV/MMAE-resistant models anti-Nectin-4 Antibody • Higher Bystander Effect than EV, • High affinity leading to stronger activity i
Slide 20: IPH4502 has broad potential in Nectin-4 expressing solid tumors
ADC IPH4502 has broad potential in Nectin-4 expressing solid tumors • IPH4502 is a next-generation differentiated Nectin-4 exatecan ADC with high internalization and bystander effect • Linker’s hydrophilicity and stability translate into high ADC exposure and low release of free exatecan into cynomo
Slide 21: IPH4502: Differentiated Nectin-4 ADC for low expressing and Padcev resistant tumors
ADC IPH4502: A differentiated Nectin-4 targeted ADC with potential to show efficacy in moderate to low Nectin-4 expressing and Padcev resistant tumors 100 OPPORTUNITIES No Nectin-4 drug approved % of Nectin-4 expressing 80 • PADCEV (enfortumab vedotin, EV) is approved tumor samples in bladder cancer
Slide 22: IPH4502: Efficacy across Nectin-4 expression levels, superior to EV in bladder PDX
ADC IPH4502: Shows efficacy across various Nectin-4 expression levels and demonstrates superior activity to EV in bladder PDX models H-score: 300 H-score: 180 H-score: 100 Nectin-4 expression 2000 2000 2000 Vehicle Tumor volume (mm3) Tumor volume (mm3) Tumor volume (mm3) 1500 1500 1500 EV 4 mg/kg 10
Slide 23: IPH4502: In vivo efficacy in heterogeneous Nectin-4 tumors via bystander effect
ADC IPH4502: Demonstrates in vivo potential for efficacy in heterogenous Nectin-4 expressing tumors via target-dependent bystander effect Nectin-4+ cells Nectin-4 KO cells Nectin-4+ cells + Nectin-4 KO cells Tumor volume (mm3) In vivo bystander killing Address heterogeneous Nectin-4 expression 24
Slide 24: IPH4502: Anti-tumor activity in a PDX-model of acquired EV-resistance
ADC IPH4502: Anti-tumor activity in a PDX-model of acquired EV-resistance Efficacy in model of EV acquired resistance Address post-EV patients 25
Slide 25: IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term
ADC IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term IPH4502 Phase 1 in Nectin-4 expressing tumors Start basket trial in combination with SOC Preliminary safety and activity signal in tumor types with low Readout from dose Dose FPI in Phase 1 and high Nectin-4 express
Slide 26: Current Late-Stage Assets
Current Late-Stage Assets 27
Slide 27: Lacutamab: Phase 3 ready proprietary asset with path to accelerated FDA approval
lacutamab Lacutamab (KIR3DL2): Phase 3 ready proprietary asset with path to accelerated FDA approval Lacutamab under development for treatment of First-in-class anti-KIR3DL2 humanized Cutaneous T-cell lymphomas (CTCL) and Peripheral T Cell Lymphomas (PTCL). cytotoxicity-inducing antibody Phase 2 dat
Slide 28: Lacutamab: Phase 2 data in Sézary syndrome patients with high unmet need
lacutamab Lacutamab: Compelling Phase 2 data in Sézary syndrome patients with high unmet need and limited treatment options Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Patient characteristics 56 post mogamulizumab patients with advanced
Slide 29: Lacutamab: Strong Phase 2 results in heavily pretreated Mycosis fungoides
lacutamab Lacutamab: Strong Phase 2 results in heavily pretreated Mycosis fungoides Best Overall Response by KIR3DL2 Expression Level KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) Data cutoff: Oct 13, 2023 Patient characteristics (N=107) Efficacy results 4 median lines of prior therapy Olsen 2011 Global OR
Slide 30: TELLOMAK data support lacutamab as a potential new SoC in MF & SS
lacutamab TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population Expansion All comers Line Expansion ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1
Slide 31: Lacutamab: Moving Towards Registrational Trial
lacutamab Lacutamab: Moving Towards Registrational Trial Phase 3 in CTCL Phase 3 readout CTCL Partnership AA submission discussions 2025 2026 2027 + Phase 2 KILT in PTCL PTCL PTCL Phase 2 data Data will inform next steps 32 CTCL: cutaneous T cell lymphome; AA: accelerated approval; PTCL: peripheral
Slide 32: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Monalizumab blocks the NKG2A • Three Phase 2 Trials completed inhibitory receptor on both NK cells and supporting rationale of cytotoxic CD8+ T cells. combination in early NSCLC • COAST • NeoCOAST • NeoCOAST
Slide 33: Monalizumab development in lung cancer
MONALIZUMAB Monalizumab development in lung cancer Phase 2 NeoCOAST Phase 2 COAST Clinical Stg I-IIIA NSCLC Unresect. Stg III NSCLC monalizumab + durvalumab monalizumab + durvalumab studies in In progress In progress Phase 2 NeoCOAST-2 Phase 3 PACIFIC-9 NSCLC 999 pts Stg II-IIIA NSCLC Unresect. Stg
Slide 34: Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73)
ADENOSINE Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73) IPH5301 Perrot et al. 2019 Cell Reports - Allard B. et al. Immunol.l Rev.. 2017 - Vigano S. et al. Front. Immunol. 2019 - Kepp O. et al. EMBO J. 2021 - ATP : adenosine triphosphate - AMP : adenosine monophosphate 35
Slide 35: IPH5201: Phase 2 clinical trial MATISSE initiated
IPH5201 IPH5201: Phase 2 clinical trial MATISSE initiated Phase 1 in advanced solid tumors Preclinical data Phase 2 trial MATISSE ongoing completed (sponsor: AstraZeneca) Best change in tumor size from baseline Non small cell lung cancer (NSCLC) IPH5201 monotherapy IPH5201 + durvalumab Neoadjuvant c
Slide 36: IPH5301: Phase 1 clinical trial CHANCES ongoing
IPH5301 IPH5301: Phase 1 clinical trial ISS CHANCES ongoing Preclinical data Phase 1 CHANCES IST ongoing (sponsor: IPC) IPH5301 epitope translates into superior blocking capacity on both membrane and soluble CD73 and superior T cell activation; IPH5301 has the potential to enhance PD-1 efficacy Adva
Slide 37: Financial highlights of our partnered assets
Financial highlights of our partnered assets 38
Slide 38: Strategic partnership with AstraZeneca: Monalizumab
MONALIZUMAB Strategic partnership with AstraZeneca Monalizumab Amounts received Total amount of the agreement: 1.275 billion US$ Total milestones Milestone Initial payments 250 100 payments Development and regulatory 50 50 400 In US$ million Commercialization 425 Royalties Outside Europe Europe on s
Slide 39: Strategic partnership with AstraZeneca: IPH5201
IPH5201 Strategic partnership with AstraZeneca IPH5201 Milestone payments $60m Potential total amount of the Already received agreement Including $5 million in milestone payment for the launch of the MATISSE Phase 2 trial. $885 million Royalties on sales Outside Europe AstraZeneca will record all sa
Slide 40: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Three molecules licensed to Sanofi plus one undisclosed target remaining under option IPH6101/SAR’579 IPH6401/SAR’514 IPH62 OPTION Ongoing CD123 BCMA B7-H3 Target undisclosed programs Phase 1 / 2 in AML Phase 1 / 2 in Multiple Myeloma Research P
Slide 41: Key takeaways
@ innate pharma Key takeaways 42
Slide 42: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 safety and IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 clinical data preliminary efficacy data Proprietary IPH4502 ADC (Nectin-4 ADC) | Phase 1 safety and preliminary IPH4502 ADC (Nectin-4 ADC) | Phase 1 ongoing efficacy data
Slide 43: Key Takeaways
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • EXPAND ANKET® CLINICAL PORTFOLIO • Phase 1/2 clinical trial underway with IPH6501, a proprietary 2nd generation CD20 ANKET® in B-cell NHL • SAR’579/IPH6101 (CD123 ANK
Slide 44: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA